How do Hemadid (ferrous sulfate), Globifer (iron polymaltose/iron protein succinylate), and Fefol Spansules (iron‑folic‑acid combination) compare regarding efficacy, elemental iron content, side‑effect profile, and which is considered best based on available studies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comparison of Hemadid (Ferrous Sulphate), Globifer, and Fefol Spansules

Critical Error in Evidence Provided

The evidence provided contains FDA labeling for "Hemadid" which is actually dexamethasone (a corticosteroid), NOT ferrous sulphate. 1 This appears to be a database error. I will answer based on the actual iron formulations you're asking about: ferrous sulphate, iron polymaltose complex (IPC)/iron protein succinylate, and iron-folic acid combinations.

Direct Recommendation

Start with standard ferrous sulphate (200 mg tablet = 65 mg elemental iron) once daily for iron deficiency anemia, as it is more effective than iron polymaltose complex at raising hemoglobin levels, despite causing more gastrointestinal side effects. 2, 3, 4


Elemental Iron Content

Ferrous Sulphate (Hemadid)

  • 200 mg tablet = 65 mg elemental iron 2
  • Most cost-effective: ~£1.00 per 28 days 2

Iron Polymaltose Complex (Globifer - if IPC formulation)

  • 100 mg elemental iron per dose (typical)
  • Significantly more expensive than ferrous salts 2

Fefol Spansules (Ferrous Sulphate + Folic Acid)

  • Modified-release: 150 mg = 48 mg elemental iron OR 325 mg = 105 mg elemental iron 2
  • Note: Modified-release preparations are listed as "less suitable for prescribing" in British guidelines 2
  • Cost: £2.58-3.95 per 28 days 2

Efficacy Comparison

Ferrous Sulphate is Superior

High-quality evidence demonstrates ferrous sulphate raises hemoglobin significantly more than iron polymaltose complex:

  • Mean difference of 0.81 g/dL higher hemoglobin with ferrous sulphate vs IPC (95% CI 0.53-1.08; P<0.001) 3
  • Ferritin levels: 21.24 mcg/L higher with ferrous sulphate (95% CI 3.23-39.26; P=0.020) 3
  • MCV improvement: 3.20 fL greater with ferrous sulphate (P=0.003) 3

In pediatric populations, ferrous sulphate showed mean hemoglobin increase of 0.53 g/dL more than other iron compounds (P<0.001) 4

Iron Protein Succinylate (Alternative to IPC)

If Globifer contains iron protein succinylate rather than IPC:

  • Equally effective as ferrous sulphate in restoring hemoglobin, hematocrit, and iron stores within 15 days 5
  • Does not increase serum hepcidin (unlike ferrous salts), potentially advantageous in inflammatory conditions 5
  • Minimal intestinal iron deposition compared to ferrous sulphate 5

Modified-Release Formulations (Fefol Spansules)

Avoid modified-release and enteric-coated preparations:

  • Release iron beyond the duodenum/proximal jejunum where absorption is optimal 2
  • British guidelines specifically note these are "less suitable for prescribing" 2
  • May improve tolerability but decrease absorption 6

Side Effect Profile

Gastrointestinal Adverse Effects

Ferrous sulphate causes significantly more GI side effects:

  • 78% vs 31% adverse effects (ferrous sulphate vs IPC; P<0.001) 7
  • 34.1% vs 14.9% adverse drug reactions in adults (ferrous sulphate vs IPC; P<0.001) 8
  • Specific issues: Upper digestive troubles, stained teeth, diarrhea more common with ferrous salts 8

In pediatric meta-analysis:

  • Increased GI side effects with ferrous sulphate vs IPC (P=0.03) 4
  • However, no significant difference in overall adverse events in some pediatric trials 9

Compliance Impact

Better compliance with IPC formulations:

  • 91% compliance with IPC vs 87% with ferrous sulphate (P<0.05) 7
  • Lower dropout rates due to tolerability 3

Clinical Algorithm for Selection

First-Line Choice

  1. Start with ferrous sulphate 65-100 mg elemental iron once daily 6, 2
    • Take on empty stomach for maximum absorption
    • If GI intolerance develops, try with food (accept reduced absorption)
    • Alternate-day dosing (100-200 mg elemental iron) may improve tolerability and absorption 2

Second-Line (If Intolerance to Ferrous Sulphate)

  1. Switch to iron protein succinylate or IPC
    • Equivalent efficacy for iron protein succinylate 5
    • Slightly lower efficacy for IPC but clinically meaningful improvement still achieved 3
    • Better tolerated with fewer GI effects 7, 8
    • Consider in patients with inflammatory conditions (hepcidin advantage) 5

Avoid

  1. Do NOT use modified-release preparations (Fefol Spansules) as first-line
    • Suboptimal absorption 2
    • Designated "less suitable for prescribing" 2
    • Only consider if standard preparations completely intolerable

Folic Acid Supplementation

  • Add folic acid separately if needed (pregnancy, malabsorption)
  • Don't rely on combination products with suboptimal iron formulations 2

Dosing Strategy Based on Current Evidence

Lower doses may be equally effective with better tolerability:

  • Historical recommendation: 150-200 mg elemental iron daily 6
  • Emerging evidence supports 50-100 mg elemental iron once daily or alternate-day dosing 2
  • Hepcidin elevation from 60 mg elemental iron reduces subsequent absorption by 35-45% 2

Monitoring Response

Expect hemoglobin rise of ≥10 g/L within 4 weeks 2

If no response:

  • Assess adherence (side effects are common cause)
  • Consider malabsorption
  • Evaluate ongoing blood loss
  • Check for concurrent B12/folate deficiency
  • Consider switch to alternative oral formulation or parenteral iron 6, 2

Key Caveats

  1. Cost vs. Tolerability Trade-off: Ferrous sulphate is most effective and cheapest but least tolerated 2, 3

  2. Pregnancy Consideration: Both ferrous sulphate and IPC are effective in pregnancy; IPC may be preferred if tolerability is an issue 7

  3. Inflammatory Conditions: Iron protein succinylate may have theoretical advantage (no hepcidin increase) 5, though clinical significance requires further study

  4. Pediatric Use: Ferrous sulphate remains most effective despite higher side effects 4; consider liquid formulations for dosing flexibility 2

  5. Modified-Release Products: The spansule technology in Fefol may reduce bioavailability—this is a significant limitation 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.